Novartis has secured a $120 million upfront deal with Boston-based Monte Rosa Therapeutics to develop molecular glue degraders targeting immune-mediated diseases, with potential payments up to $5.7 billion. This marks Novartis’s second collaboration with Monte Rosa, broadening their portfolio in protein degradation therapies. Monte Rosa will continue discovery and early testing, after which Novartis may license chosen programs. Monte Rosa aims to advance multiple candidates into clinical phases with this financing. This collaboration underscores a major pharma's belief in targeted protein degradation as a promising therapeutic approach.